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Dear Editor,
Bipolar disorder (BD) is a chronic pathology with a worldwide 
prevalence of 2.4% in its classic presentations1. Studies show that the 
depressive, mania/hypomania crises are neurotoxic and cognitive 
impairment is present both in the acute phases as well as in euthymia. 
However, bipolar type I patients have more cognitive changes than 
type II patients, most likely due to greater toxicity of manic episodes, 
with greater release of inflammatory cytokines, reduction of brain-
derived neurotrophic factor (BDNF), higher oxidative stress and, 
consequently, loss of neuroprotective mechanisms2. In this sense, 
more than the time of disease duration, the number of manic episodes 
seems to determine the exacerbation of cognitive decline, mainly in 
patients presenting psychotic symptoms2,3. 
In BD patients, cognitive deficits are found in several domains, 
such as processing speed, visuospatial abilities, verbal memory and 
attention, with the last two being the most impaired3. Furthermore, 
evidence shows that these deficits are associated with total brain 
atrophy, enlargement of the lateral ventricles, decrease of the corpus 
callosum volume, and the reduction of the hippocampus, findings 
that are also found in neurodegenerative diseases such as dementia4,5. 
Besides that, according to the theory of neuroprogression in BD 
stage 4, there are loss of autonomy due to cognitive and functional 
impairment, associated with enlargement ventricle and/or white 
matter hyperintensities, increase of tumor necrosis factor α (TNF-α), 
increase of nitrotyrosine 3, decrease of BDNF, increase of interleukins 
6, 10, and glutathione transferase4. 
So, although several studies point to BD as a risk factor for 
dementia, we question whether the cognitive dysfunctions present 
in some of these patients are not enough to affirm that there also 
a “bipolar dementia”, just like it’s done in other pathologies such 
as Parkinson’s disease6 and epilepsy7. In fact, Parkinson’s disease, 
epilepsy and BD patients who develop cognitive dysfunction do 
not present the changes in the cerebrospinal fluid as are described 
in Alzheimer’s disease, such as low concentrations of beta amyloid 
protein and high concentrations of total and phosphorylated tau 
protein5. In BD, like in these diseases, there is cognitive impairment; 
the deficits emerge over time with the recurrence of crises and there 
is no evidence pointing to a related or altered specific substance, 
leading to neurodegeneration3. 
Recognizing BD as a pathology that might cause a subtype of 
dementia is important to reinforce the need for adequate diagnosis 
and treatment, bearing in mind the loss of functionality of the patients 
who present cognitive deficits. Furthermore, we should remember 
that BD has a high comorbidity with metabolic syndrome, which 
may also contribute toward microangiopathy and vascular dementia 
scenarios, whose physiopathology is different from dementia due 
to neurodegeneration. Thus, we pose the following question: is BD 
only a risk factor for dementia or must be considerate a distinct 
clinical entity?
Disclosure
The authors report no conflicts of interest.
References
1.  Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, 
Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spec-
trum disorder in the national comorbidity survey replication. Arch Gen 
Psychiatry. 2007;64(5):543-52. 
2.  Piccinni A, Marazziti D, Callari A, Franceschini C, Veltri A, Bartolommei 
N, et al. Bipolar disorder and dementia: a close link. Clin Neuropsychiatry. 
2015;12(2):27-36. 
3.  Cardoso T, Bauer IE, Meyer TD, Kapczinski F, Soares JC. Neuroprogres-
sion and cognitive functioning in bipolar disorder: a systematic review. 
Curr Psychiatry Rep. 2015;17(9). 
4.  Roda A, Chendo I, Kunz M. Biomarkers and staging of bipolar disorder: 
a systematic review. Trends Psychiatry Psychother. 2015;37(1):3-11. 
5.  Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZA, 
Stella F, et al. Cognitive impairment in late-life bipolar disorder is not 
associated with Alzheimer’s disease pathological signature in the cere-
brospinal fluid. Bipolar Disord. 2016;18(1):63-70. 
6.  Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. 
J Neurol Sci. 2017;374(2016):26-31. 
7.  Breuer LEM, Grevers E, Boon P, Bernas A, Bergmans JWM, Besse-
ling RMH, et al. Cognitive deterioration in adult epilepsy: clinical 
characteristics of “Accelerated Cognitive Ageing.” Acta Neurol Scand. 
2017;136(1):47-53. 
